Table 3.

Treatment-related AEs experienced by ≥5% of patients

AEsAll gradesa, n (%)Grade 3, n (%)
Any AE20 (87.0)5 (21.7)
Dysgeusia15 (65.2)0
Fatigue12 (52.2)1 (4.3)
Nausea8 (34.8)0
Decreased appetite8 (34.8)1 (4.3)
Dizziness7 (30.4)1 (4.3)
Diarrhea6 (26.1)0
Dehydration6 (26.1)1 (4.3)
Vomiting5 (21.7)0
Muscle spasms5 (21.7)0
Alopecia5 (21.7)0
Anemia2 (8.7)0
Palpitations2 (8.7)0
Constipation2 (8.7)0
Gastroesophageal reflux2 (8.7)0
Headache2 (8.7)0
Pruritus2 (8.7)0
ALT increased2 (8.7)1 (4.3)
AST increased2 (8.7)1 (4.3)
Alkaline phosphatase increased2 (8.7)0
Bilirubin increased2 (8.7)0
Creatinine increased2 (8.7)0
Weight decreased2 (8.7)0

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

  • aNone of the patients experienced a treatment-related grade 4 or 5 AE.